Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Generate Biomedicines Q3 2026 Results: Net Loss of $87.7M, Loss Widens

Generate Biomedicines, Inc. is a clinical-stage biotechnology company utilizing its AI-driven 'Generate Platform' for drug discovery. As of October 29, 2026, the company had 129,096,666 shares of common stock outstanding and is classified as an emerging growth company and a non-accelerated filer.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue4.29.6
Profit before tax-87.6-60.0
Net income-87.7-53.6
EPS (diluted, $ a share)$-0.68$-1.97

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-56.2%
Source

10-Q filed with the SEC, NASDAQ: GENB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Generate Biomedicines, Inc.: key numbers

Share price
$9.84Close, Nov 17
Market cap
$1.27B
Shares outstanding
129.1MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Generate Biomedicines, Inc.

All →
7:16 AM ET 8-K
Financial Results

Generate Biomedicines Financial Results

Generate Biomedicines reported third quarter 2026 financial results, highlighting a cash position of $404.2 million and progress in its Phase 3 asthma studies for GB-0895. The company also noted a significant collaboration with Zealand Pharma in obesity and metabolic diseases with total potential milestones of nearly $1.2 billion.

“Our third quarter results reflect both strong execution across all of our clinical programs and our continued efforts to push the frontiers of programmable biology and therapeutic intelligence. We are making strong progress with GB-0895 in severe asthma, and the data we shared at ERS in COPD further demonstrated the sustained pharmacological activity to support robust modulation of key biomarkers and twice-a-year dosing.”

Mike Nally, chief executive officer of Generate Biomedicines
4:05 PM ET Form 4
Insider Selling

Generate Biomedicines Director Frances Arnold Sells $185K of Stock

Frances Arnold, Director, sold 11,409 shares of Generate Biomedicines, Inc. at $16.19 a share, worth $185K in total on Oct 29, 2026. Shares held after the trade: 220,063 (-4.9%).

Value
$185K
Shares
11,409
Price
$16.19
Role
Director
Holding change
-4.9%
Trade date
Oct 29, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.